To prevent cervical cancer, 1,700 adolescents and women from San Carlos are immunized against human papillomavirus (HPV).
The work is being carried out by the Costa Rica Agency for Biomedical Research (ACIB) as part of the study to prove that one dose is as effective as applying two.
The vaccination process began on December 7 and will continue until February 2020, while participants will be recruited and monitored for another four years.
Data from the National Registry of Tumors indicate that in the Canton of Alghero and those that 25 women died of cervical cancer between 2011 and 2015. That is, the rate of 5.6 cases per 100,000 women per year.
"Cervical cancer continues to claim the lives of hundreds of thousands of women each year, especially in the poorest countries, so we have tools to prevent it, such as early detection of the HPV vaccine," said Paula González, director of ACIB.
"The vaccine does not apply to all countries that need it because of its high cost and two doses, so we conducted the study to show that one serving is sufficient and can provide protection for more women in the world," he added.
The vaccines are being implemented in the one and second dose comparison study of Escuddo (HPV), which includes 24,000 young women and adolescents between the ages of 12 and 20 years.
This dose will be accepted by women from 50 cantons throughout the country, except for the lemon district due to the complexity of transporting samples.
So far, only 6,500 of the 24,000 women have already turned to participate in the process.
In the World Health Organization (WHO), adolescents under the age of 15 are advised to apply 2 doses and the vaccine to be included in national immunization programs in all countries.
The cervical cancer vaccine is part of the national free vaccination program in 80 countries. In Costa Rica he was approved by the Ministry of Health and will be included in the programs of the Costa Rica National Insurance Fund (CCSS) for 10 years, beginning in 2019.